{"product_id":"ptcbio-bcg-matrix","title":"PTC Therapeutics Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic potential of PTC Therapeutics with a comprehensive BCG Matrix analysis. Understand how their pipeline products are positioned as potential Stars or Question Marks, and identify which established therapies might be Cash Cows. Don't miss out on the critical insights needed to navigate their market landscape.\u003c\/p\u003e\n\u003cp\u003eDive deeper into PTC Therapeutics' product portfolio with the full BCG Matrix. Gain a clear view of where their innovations stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the complete report for a detailed breakdown and actionable strategic insights you can implement immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSephience: Imminent Global Launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSephience, a promising treatment for Phenylketonuria (PKU), is on the cusp of a major global rollout.  Following a positive opinion from the CHMP in April 2025, the U.S. FDA has set a target action date of July 29, 2025, signaling strong regulatory momentum. This swift advancement points to substantial market potential as Sephience transitions from approval to widespread availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSephience: Potential New Standard of Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSephience is positioned as a potential 'star' in PTC Therapeutics' BCG Matrix, representing a significant growth opportunity.  This therapy is expected to become a new standard of care for phenylketonuria (PKU) patients, targeting a market forecast to expand at a 9.4% compound annual growth rate through 2030.\u003c\/p\u003e\n\u003cp\u003eAnalysts project Sephience could achieve considerable revenue in its initial U.S. launch year, with global sales anticipated to reach $500 million by 2026, underscoring its strong market potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKebilidi\/Upstaza: First US-Approved Gene Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKebilidi, or Upstaza, marks a significant milestone as the first gene therapy approved by the U.S. FDA in November 2024 for AADC deficiency. This groundbreaking treatment is administered directly into the brain, a novel approach for this rare condition.\u003c\/p\u003e\n\u003cp\u003eIts first-to-market status in the United States for AADC deficiency is a key strength, suggesting strong potential for early and substantial market penetration. This positions Kebilidi as a potential star product for PTC Therapeutics, given the unmet medical need it addresses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKebilidi\/Upstaza: Addresses High Unmet Medical Need\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKebilidi (upadacitinib) represents a significant advancement in treating AADC deficiency, a severe and rare genetic disorder. This condition has historically presented a critical unmet medical need, as there were limited effective treatment options. Kebilidi's innovative one-time gene therapy approach aims to provide lasting benefits, addressing the core genetic defect and offering a new paradigm for patient care.\u003c\/p\u003e\n\u003cp\u003eThe drug's clinical significance is underscored by its approval and established market presence in the European Union and the United Kingdom since 2022. This early adoption demonstrates its recognized therapeutic value and paves the way for its potential rapid uptake in other markets as regulatory approvals expand. For instance, in 2023, Kebilidi received FDA approval in the United States, further broadening its reach to patients with this debilitating condition.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAddresses Critical Unmet Need:\u003c\/strong\u003e Kebilidi targets AADC deficiency, a fatal rare genetic disorder with limited prior treatment options.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInnovative Gene Therapy:\u003c\/strong\u003e Its one-time gene therapy approach offers potential for long-term, lasting benefits for patients.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEstablished Market Presence:\u003c\/strong\u003e Approved in the EU and UK since 2022, and the US in 2023, highlighting its clinical utility and market acceptance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSignificant Patient Impact:\u003c\/strong\u003e AADC deficiency affects approximately 1 in 100,000 newborns, making Kebilidi a vital therapeutic option for a vulnerable population.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Growth Assets Leveraging Rare Disease Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSephience and Kebiidi stand out as high-growth assets within PTC Therapeutics' portfolio, reflecting a strategic emphasis on rare diseases. These therapeutic areas often present substantial market potential due to unmet medical needs and limited competition, positioning these products as key drivers of future revenue. For instance, the rare disease market is projected to grow significantly, with some estimates suggesting a compound annual growth rate exceeding 10% in the coming years, underscoring the strategic importance of these assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eSephience and Kebiidi: Pillars of Rare Disease Strategy\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHigh Growth Potential in Unmet Medical Needs\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSignificant Future Revenue Drivers for PTC Therapeutics\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCritical for Sustaining Company Growth Trajectory\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePTC Therapeutics' Stars: Sephience \u0026amp; Kebiidi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSephience and Kebiidi are PTC Therapeutics' prime candidates for 'star' status within the BCG matrix, driven by their strong market potential in rare diseases. Sephience, targeting phenylketonuria (PKU), is poised for global rollout with a U.S. FDA action date of July 29, 2025, in a market expected to grow at 9.4% annually through 2030. Kebiidi, the first gene therapy for AADC deficiency approved in the U.S. in November 2024, addresses a critical unmet need and has already seen success in Europe since 2022.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eBCG Category\u003c\/th\u003e\n\u003cth\u003eMarket Growth\u003c\/th\u003e\n\u003cth\u003eProjected Sales (2026)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSephience\u003c\/td\u003e\n\u003ctd\u003ePhenylketonuria (PKU)\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003e9.4% CAGR\u003c\/td\u003e\n\u003ctd\u003e$500 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKebiidi\u003c\/td\u003e\n\u003ctd\u003eAADC Deficiency\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003eHigh (addressing unmet need)\u003c\/td\u003e\n\u003ctd\u003eSignificant potential\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003ePTC Therapeutics' BCG Matrix offers a strategic overview of its product portfolio, categorizing them as Stars, Cash Cows, Question Marks, or Dogs.\u003c\/p\u003e\n\u003cp\u003eThis analysis guides investment decisions, highlighting which therapeutic areas warrant further development, maintenance, or divestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA clear BCG matrix for PTC Therapeutics' pipeline, highlighting growth opportunities and resource allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmflaza: Established Duchenne Muscular Dystrophy Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmflaza, a key treatment for Duchenne muscular dystrophy (DMD), continues to be a strong revenue generator for PTC Therapeutics. In the first quarter of 2025, it brought in $47.8 million. This demonstrates its established position in the market, even with the emergence of new generic alternatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmflaza: Provides Foundational Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmflaza, a key treatment for Duchenne Muscular Dystrophy (DMD) in patients aged 5 and above, serves as a foundational cash cow for PTC Therapeutics. Its established market presence ensures a reliable and consistent revenue stream, a vital component for the company's financial stability.\u003c\/p\u003e\n\u003cp\u003eThis stable income from Emflaza is instrumental in powering PTC's significant investments in research and development. For instance, in 2023, PTC Therapeutics reported net product revenue from Emflaza of $107.2 million, highlighting its contribution to funding the development of new therapies and expanding its promising pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvrysdi Royalties: Stable and Predictable Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvrysdi royalties represent a strong Cash Cow for PTC Therapeutics, providing a stable and predictable income stream.  This royalty revenue, generated from Roche's successful sales of Evrysdi for Spinal Muscular Atrophy (SMA), is a testament to the drug's market penetration and therapeutic value.\u003c\/p\u003e\n\u003cp\u003eIn the first quarter of 2025, PTC Therapeutics reported $36.4 million in royalty revenue from Evrysdi. This figure highlights the consistent and growing financial contribution of this product, solidifying its position as a reliable income generator within PTC's portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvrysdi Royalties: Low Investment, High Return\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEvrysdi royalties represent a prime example of a cash cow for PTC Therapeutics. This revenue stream requires very little ongoing investment from PTC, allowing them to capitalize on past development and commercialization efforts without significant new capital outlay. Essentially, PTC can passively generate substantial income from Evrysdi.\u003c\/p\u003e\n\u003cp\u003eThe efficiency of Evrysdi royalties is a key characteristic of a cash cow. PTC's role is largely limited to managing the royalty agreements, rather than bearing the costs of production, marketing, or further research and development for the drug itself. This focus on passive income generation is what defines its cash cow status.\u003c\/p\u003e\n\u003cp\u003eHere are some key aspects of Evrysdi royalties as a cash cow:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMinimal Ongoing Investment:\u003c\/strong\u003e PTC's direct financial commitment to Evrysdi's ongoing success is significantly reduced, allowing for high profit margins.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePassive Income Generation:\u003c\/strong\u003e The royalty model enables PTC to benefit from Evrysdi's sales without active operational involvement in its day-to-day business.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrong Profitability:\u003c\/strong\u003e As sales of Evrysdi continue, PTC receives a percentage of revenue, contributing significantly to its overall financial health and providing capital for other ventures.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Leadership:\u003c\/strong\u003e Evrysdi's strong market position in treating spinal muscular atrophy (SMA) underpins the consistent and substantial royalty income PTC receives.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFoundational Financial Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePTC Therapeutics benefits from significant financial stability, largely due to the consistent cash flow generated by its established products. Emflaza and the royalties from Evrysdi are key contributors, acting as the company's cash cows.\u003c\/p\u003e\n\u003cp\u003eThis reliable income stream provides a strong financial bedrock. As of March 2025, PTC Therapeutics reported a cash position exceeding $2 billion. This substantial liquidity allows the company to comfortably fund its ongoing operations and pursue strategic growth initiatives without the immediate pressure of seeking external capital.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eConsistent Cash Generation:\u003c\/strong\u003e Emflaza and Evrysdi royalties provide a steady income.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRobust Financial Foundation:\u003c\/strong\u003e Over $2 billion in cash as of March 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperational and Strategic Support:\u003c\/strong\u003e Funds ongoing operations and new investments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReduced Capital Needs:\u003c\/strong\u003e Eliminates the immediate need for additional financing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmflaza \u0026amp; Evrysdi: Cash Cows Fueling Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmflaza and Evrysdi royalties are PTC Therapeutics' primary cash cows, providing consistent revenue with minimal reinvestment. In Q1 2025, Emflaza generated $47.8 million, while Evrysdi royalties contributed $36.4 million. These established products, with strong market positions, form the financial backbone of the company, enabling significant investment in its pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eRevenue Type\u003c\/th\u003e\n\u003cth\u003eQ1 2025 Revenue\u003c\/th\u003e\n\u003cth\u003e2023 Full Year Revenue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmflaza\u003c\/td\u003e\n\u003ctd\u003eNet Product Revenue\u003c\/td\u003e\n\u003ctd\u003e$47.8 million\u003c\/td\u003e\n\u003ctd\u003e$107.2 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvrysdi\u003c\/td\u003e\n\u003ctd\u003eRoyalty Revenue\u003c\/td\u003e\n\u003ctd\u003e$36.4 million\u003c\/td\u003e\n\u003ctd\u003eN\/A (Royalty data not provided for 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003ePTC Therapeutics BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe PTC Therapeutics BCG Matrix preview you are currently viewing is the identical, fully unlocked document you will receive immediately after your purchase. This means you'll get the complete, professionally formatted analysis without any watermarks or placeholder content, ready for immediate strategic application.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610830913913,"sku":"ptcbio-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ptcbio-bcg-matrix.png?v=1754747047","url":"https:\/\/growthsharematrix.com\/products\/ptcbio-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}